Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
Immunotherapy holds great promise in cancer treatment. The challenges in advancing immunotherapies lie in patient stratification and monitoring therapy. Noninvasive detection of immune checkpoint ligand PD-L1 can serve as an important biomarker for guidance and monitoring of immunotherapy. Here in,...
Saved in:
| Main Authors: | Samit Chatterjee PhD, Wojciech G. Lesniak PhD, Sridhar Nimmagadda PhD |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-07-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.1177/1536012117718459 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development of [F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide
by: Wojciech G. Lesniak PhD, et al.
Published: (2019-06-01) -
Immune Checkpoint Inhibitors in Kidney Transplant Recipients: A French Multicenter Retrospective Cohort Study
by: Tristan Legris, MD, et al.
Published: (2025-09-01) -
Magnetic Resonance Imaging for Characterization of a Chick Embryo Model of Cancer Cell Metastases
by: Anne Herrmann PhD, et al.
Published: (2018-10-01) -
Post-discontinuation Survival in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Pooled Analysis of Prospective Cohort Studies
by: Yusuke Inoue, MD, PhD, et al.
Published: (2025-08-01) -
Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: A clinical case series of a diverse spectrum
by: Nika Kotnik, MD, et al.
Published: (2025-07-01)